ACTR5 and hepatocellular carcinoma: Last, suppression of ACTR5 significantly retarded the in vivo HCC tumor progression (Fig. 1G) and reduced the tumor mass (Fig. 1H; sgiNTC = 0.537 ± 0.097 g; sgiACTR5 = 0.013 ± 0.006 g; data represent day 24 mean tumor weight ± SEM) in the HepG2 xenograft model, indicating the indispensable role of ACTR5 in HCC maintenance.